Organoid Science is experiencing a strong performance. News that the company is aiming to sign joint research and solution supply agreements with global corporations this year appears to be influencing its stock price.
As of 9:33 a.m. on May 14, the stock was trading at 39,600 won, up 8.79% from the previous day.
Yoo Jongman, CEO of Organoid Science, recently stated in a media interview, "Orders from global big pharma companies have recently begun in earnest," and added, "Starting this year, we expect to demonstrate tangible achievements in overseas expansion."
Organoid Science's main products are the regenerative therapy 'ATORM', which utilizes 'organoid' technology that recreates human organs by culturing stem cells in three dimensions, and the new material efficacy evaluation solution 'ODISEI'. The company is currently conducting advanced regenerative medicine clinical trials for ATORM, and since commercializing ODISEI in Korea for the first time in 2020, it has continued to secure orders from major domestic conglomerates, large hospitals, and government agencies. More recently, the company has also begun to secure overseas orders from global pharmaceutical companies.
The company is actively expanding its business areas. Through subsidiaries located in Germany and Vietnam, it is accelerating its entry into the global market, focusing on Europe, North America, and Southeast Asia as key hubs. It is also expanding its business portfolio by applying organoid technology to various fields, including health functional foods and cosmetics. In fact, a precision medicine companion diagnostic service for cancer patients was recently launched at Severance Hospital. In addition, leveraging its advanced biopharmaceutical production capabilities and expertise in Good Manufacturing Practice (GMP) operations, the company is pursuing a contract development and manufacturing organization (CDMO) business for researchers.
The regenerative therapy market is expected to experience explosive growth. According to the global market research firm Fortune Business Insight, the global regenerative therapy market is expected to grow from $42 billion (KRW 6.0417 trillion) last year to $398 billion (KRW 57.2523 trillion) by 2032, representing an average annual growth rate of approximately 32.4%.
On May 9, the company was listed on the KOSDAQ market as the first company under the 'Super Gap Technology Special Listing' program. Since its listing, the stock price has continued to rise steadily compared to the offering price of 21,000 won.
Organoid Science plans to enter Phase 1 clinical trials in the United States and Europe next year, with the goal of completing Phase 2 by the end of 2028. The company aims to sign a large-scale technology export agreement as soon as Phase 2 is completed. CEO Yoo emphasized, "Due to confidentiality obligations, it is difficult to disclose the names of the companies, but for the past three years, we have been in continuous discussions with several global big pharma companies regarding regenerative therapies such as ATORM-C."
Recently, Organoid Science presented the short-term results of the ATORM-C intestinal organoid regenerative therapy clinical trial (conducted under the Advanced Regenerative Bio Act) at the 'European Society of Gastrointestinal Endoscopy Annual Meeting' (2025 ESGE Days) held in Spain. The study targeted patients with severe Behcet's enteritis who did not respond to existing therapies. The results represent the world's first case in which an organoid-based therapy demonstrated clinical efficacy and safety in refractory intestinal diseases, attracting attention from the regenerative medicine industry both domestically and internationally.
Behcet's enteritis is a rare inflammatory disease characterized by recurrent chronic ulcers in the intestine, which can lead to intestinal perforation, peritonitis, or, in severe cases, surgical resection. For patients who do not respond to existing autoimmune disease treatments such as Humira (adalimumab), there are few alternative therapies available, making it a disease with significant unmet medical needs.
The study found that the technical success rate of autologous intestinal organoid culture was 80%, and ulcer healing was observed in three out of four patients (75%) who received the therapy. All patients (100%) showed improvement in clinical symptoms, and no serious adverse events occurred.
Professor Lee Beomjae of the Department of Gastroenterology at Korea University Guro Hospital, who led the clinical trial, stated, "ATORM-C could be a meaningful alternative for patients with refractory Behcet's enteritis who do not respond to existing therapies," and added, "We plan to continue evaluating potential risks, such as tumor development, through long-term follow-up over the next three years."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
